Levodopa with carbidopa (Sinemet): Supply issue
Levodopa with carbidopa is a medicine used in the treatment of Parkinson’s Disease.
On this page:
- Supply issue resolved
- One presentation remains out of stock
- Information for pharmacists
- Information for prescribers
- Information for people taking levodopa with carbidopa
- Who to contact
There has been an ongoing supply issue with the Sinemet (immediate release) and Sinemet CR (modified release) brands of levodopa with carbidopa supplied by Merck Sharpe and Dohme.
During this supply issue, people may have received an alternative brand.
The Sinemet immediate release supply issue is now resolved.
Merck Sharpe and Dohme have informed us that Sinemet will be available again as follows:
- Sinemet, levodopa 100 mg + carbidopa 25 mg tab (immediate release) from mid May
- Sinemet, levodopa 250 m g + carbidopa 50 mg tab (immediate release) from mid May
Some people taking levodopa with carbidopa will only have used the Kinson brand supplied by Mylan. Taking Sinemet will be a change of brand for them. For many others, Sinemet will be a return to a brand they had been using before.
Sinemet CR, levodopa 200 mg + carbidopa 50 mg (modified release), also supplied by Merck Sharpe and Dohme, remains out of stock. Mylan is suppling an alternative brand under Section 29.
Merck Sharpe and Dohme is working to resolve this supply issue and Sinemet CR is expected to be available later this year. We will provide an update when dates are confirmed.
The Kinson brand of levodopa with carbidopa 100/25 immediate release will be delisted in late 2020, (likely 1 December 2020), to allow stock in the supply chain to be dispensed to patients and claimed for.
The Sinemet brand of levodopa with carbidopa 250/25 immediate release will be available from mid-May.
Sinemet CR, levodopa 200 mg + carbidopa 50 mg (modified release), remains out of stock. Mylan is suppling an alternative brand under Section 29.
Merck Sharpe and Dohme advise that Sinemet CR is expected to be available later this year. We will provide an update when dates are confirmed.
The Pharmaceutical Schedule will be updated each month with the appropriate funded products.
For further information please see the letter sent by Merck Sharpe and Dohme to Healthcare Professionals, dated 29 April 2020.
Until recently, there has been a supply issue with the Sinemet and Sinemet CR brands of levodopa with carbidopa. To ensure continuity of supply of this medicine some alternative brands have been funded over the last two years.
The supply issue with Sinemet and Sinemet CR is now resolving so patients will be dispensed the Sinemet and Sinemet CR brands again as each strength becomes available.
Some of your patients may have only been using the alternative brand of levodopa and carbidopa, supplied by Mylan, so they may have some questions about their medicine next time they talk to you.
Medsafe have provided some advice on additional patient monitoring you may want to consider for each of your patients taking these medicines.
You may have been taking the Kinson or Mylan brand of levodopa with carbidopa. These brands were funded because there was a supply issue for the Sinemet and Sinemet CR brands of levodopa with carbidopa.
The supply issue is now resolving and so over the next couple of months, when you pick up your medicine from the pharmacy, you will start to get the Sinemet or Sinemet CR brand of levodopa with carbidopa.
If you take levodopa with carbidopa, your doctor, nurse or pharmacist are the best people to answer your questions. PHARMAC cannot comment on an individual's clinical circumastances.
If you are a prescriber or pharmacist with questions about this supply issue, email firstname.lastname@example.org
Last updated: 20 May 2020